Clinicopathologic and biological significance of Kallikrein 6 overexpression in human gastric cancer

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6800-6806

  Nagahara, Hisashi ^a,b   Mimori, Koshi ^a   Utsunomiya, Tohru ^a   Barnard, Graham F ^c   Ohira, Masaichi ^b   Hirakawa, Kosei ^b   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 6; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TESTIS CANCER;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 26444457406     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0943     Document Type: Article

References (37)

1. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
2. Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway? Biol Chem 2002; 383:1045-57.
3. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48: 1198-205.
4. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-80.
5. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
6. Anisowicz A, Sotiropoulou G, Stenman G, et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624-36.
7. Little SP, Dixon EP, Norris F, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 1997;272: 25135-42.
8. Yamashiro K, Tsuruoka N, Kodama S, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1997;1350:11-4.
9. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
10. McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
11. Magklara A, Scorilas A, Catalona WJ, et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999;45:1960-6.
12. Stenman UH. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 1999;45:753-4.
13. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
14. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-11.
15. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003;63:2771-4.
16. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-65.
17. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-41.
18. Talieri M, Diamandis EP, Gourgiotis D, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004;91:180-6.
19. Diamandis EP, Yousef GM, Soosaipillai AR, et al. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 2000;33:579-83.
20. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
21. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76: 531-6.
22. Mori M, Staniunas RJ, Barnard GF, et al. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterol 1993;105:820-6.
23. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of elongation factor-1δ mRNA expression in oesophageal carcinoma. Br J Cancer 2004;91:282-6.
24. Shibata K, Tanaka S, Shiraishi T, et al. G-protein γ7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Res 1999;59: 1096-101.
25. Mimori K, Shiraishi T, Mashino K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22: 3463-71.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
28. Tanimoto H, Underwood LJ, Shigemasa K, et al. Increased expression of protease M in ovarian tumors. Tumour Biol 2001;22:11-8.
29. Ni X, Zhang W, Huang KC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 2004;91:725-31.
30. Yousef GM, Borgono CA, Popalis C, et al. In silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res 2004;24:43-51.
31. Schuster R, Max N, Mann B, et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108:219-27.
32. Hammond SM, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000;404: 293-6.
33. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6.
34. Cohen P, Graves HC, Peehl DM, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53.
35. Rehault S, Monget P, Mazerbourg S, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001;268:2960-8.
36. Magklara A, Mellati AA, Wasney GA, et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003; 307:948-55.
37. Bernett MJ, Blaber SI, Scarisbrick IA, et al. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 2002;277:24562-70.